Trafermin

Drug Profile

Trafermin

Alternative Names: CAB 2001; Fiblast Spray; KCB-1; KCB-1B; KCB-1D

Latest Information Update: 15 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Scios
  • Developer Kaken Pharmaceutical; Olympus Corporation; Scios
  • Class Fibroblast growth factors; Peptide fragments; Vascular disorder therapies
  • Mechanism of Action Fibroblast growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Skin ulcer
  • Preregistration Periodontitis
  • Discontinued Coronary disorders; Diabetic foot ulcer; Fracture; Peripheral vascular disorders; Postmenopausal osteoporosis; Stroke

Most Recent Events

  • 31 Dec 2014 Trafermin is still in phase III trials for Periodontitis in Japan (Topical, gel)
  • 31 Dec 2014 Discontinued - Phase-II for Diabetic foot ulcer in Japan (Topical, gel)
  • 31 Dec 2014 Discontinued - Phase-II for Fracture in Japan (Topical, gel)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top